← All trials
NCT05683561
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 25, 2023
- Primary completion
- Aug 25, 2023
- Completion date
- Aug 25, 2024
- First posted
- Jan 13, 2023
- Last posted
- Jan 13, 2023
- Enrollment
- 6000
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sinocelltech Ltd.Lead sponsor
- Sinocelltech Ltd.Study chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.